These results confirmed that the anti-cancer dosage of DIM induced the activation of the NF-κB signaling pathway in GC-MSCs to secrete tumor-related factors CCL-2, IL-6, and IL-8 and promote the progression of gastric cancer cells. The gene discussed is NFKB1; the disease is neoplasm.